Integrated Programs To Bridge Molecules From Discovery Into Clinical Development

There are many challenges and considerations that drug developers face when bridging from early drug discovery to pre-clinical and onward towards the clinic. At this early stage in the development process, it is critical to partner with experienced service providers who can remove hurdles, provide technical expertise, and work together to seamlessly transition your molecule to the next phase of development.

Charles River provides medicinal chemistry, biology, drug metabolism and pharmacokinetics (DMPK), early pharmaceutics, and non-clinical safety services to support customers from early discovery up to Investigational New Drug (IND)/Clinical Trial Authorization (CTA) submission.

Quotient Sciences provides drug substance synthesis, drug product design and manufacturing, and clinical testing services, supporting customers from lead candidate selection all the way through to commercialization.

Our collaboration offers customers unique integrated programs that bridge molecules from early discovery to proof of concept (POC) and beyond. This removes obstacles from the critical path, reduces development risks, eliminates the white space in pre-clinical drug development, and shortens the pathway to clinical development. The overlap between Charles River and Quotient Sciences’ capabilities provides flexibility for customers, dedicated project teams, and a bespoke service that is tailored to each development program.